AAAAAA

   
Results: 1-25 | 26-45
Results: 1-25/45
INTERACTION OF ANTI-HIV PROTEASE INHIBITORS WITH THE MULTIDRUG TRANSPORTER P-GLYCOPROTEIN (P-GP) IN HUMAN CULTURED-CELLS
Authors: WASHINGTON CB DURAN GE MAN MC SIKIC BI BLASCHKE TF
Citation: Cb. Washington et al., INTERACTION OF ANTI-HIV PROTEASE INHIBITORS WITH THE MULTIDRUG TRANSPORTER P-GLYCOPROTEIN (P-GP) IN HUMAN CULTURED-CELLS, Journal of acquired immune deficiency syndromes and human retrovirology, 19(3), 1998, pp. 203-209
MDR1 - ROLE IN CLINICAL DRUG-RESISTANCE AND ITS REVERSAL
Authors: SIKIC BI
Citation: Bi. Sikic, MDR1 - ROLE IN CLINICAL DRUG-RESISTANCE AND ITS REVERSAL, Annals of oncology, 9, 1998, pp. 25-25
CELLULAR-RESISTANCE TO TAXANES
Authors: SIKIC BI
Citation: Bi. Sikic, CELLULAR-RESISTANCE TO TAXANES, Annals of oncology, 9, 1998, pp. 55-55
EFFECT OF THE MULTIDRUG-RESISTANCE MODULATOR VALSPODAR ON SERUM CORTISOL-LEVELS IN RABBITS
Authors: CUFER T VRHOVEC I PFEIFER M SKRK J BORSTNAR S SIKIC BI
Citation: T. Cufer et al., EFFECT OF THE MULTIDRUG-RESISTANCE MODULATOR VALSPODAR ON SERUM CORTISOL-LEVELS IN RABBITS, Cancer chemotherapy and pharmacology, 41(6), 1998, pp. 517-521
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SDZ PSC-833, A NOVEL MULTIDRUG-RESISTANCE REVERSING AGENT, IN PHASE-1 TRIALS WITH CHEMOTHERAPEUTIC-AGENTS
Authors: CHARNICK SB FRACASSO P EGORIN M SONNEVELD P BLEEHAN N GIACCONE G NIEDERBERGER W SMITH HT PEARCE T SIKIC BI
Citation: Sb. Charnick et al., PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SDZ PSC-833, A NOVEL MULTIDRUG-RESISTANCE REVERSING AGENT, IN PHASE-1 TRIALS WITH CHEMOTHERAPEUTIC-AGENTS, European journal of cancer, 33, 1997, pp. 775-775
ISIS 3521 CGP 64128A - ANTISENSE TO PROTEIN-KINASE-C/
Authors: DORR FA SIKIC BI NEMUNAITIS J ECKHARDT G YUEN AR
Citation: Fa. Dorr et al., ISIS 3521 CGP 64128A - ANTISENSE TO PROTEIN-KINASE-C/, European journal of cancer, 33, 1997, pp. 115-115
TREATMENT OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA WITH CYCLOSPORINE
Authors: ADVANI R WARNKE R SIKIC BI HORNING S
Citation: R. Advani et al., TREATMENT OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA WITH CYCLOSPORINE, Annals of oncology, 8(6), 1997, pp. 601-603
MODULATION AND PREVENTION OF MULTIDRUG-RESISTANCE BY INHIBITORS OF P-GLYCOPROTEIN
Authors: SIKIC BI FISHER GA LUM BL HALSEY J BEKETICORESKOVIC L CHEN G
Citation: Bi. Sikic et al., MODULATION AND PREVENTION OF MULTIDRUG-RESISTANCE BY INHIBITORS OF P-GLYCOPROTEIN, Cancer chemotherapy and pharmacology, 40, 1997, pp. 13-19
VALIDATION OF A LIMITED SAMPLING MODEL TO DETERMINE ETOPOSIDE AREA-UNDER-THE-CURVE
Authors: LUM BL LANE KJ SYNOLD TW GORAM A CHARNICK SB SIKIC BI
Citation: Bl. Lum et al., VALIDATION OF A LIMITED SAMPLING MODEL TO DETERMINE ETOPOSIDE AREA-UNDER-THE-CURVE, Pharmacotherapy, 17(5), 1997, pp. 887-890
PHARMACOLOGICAL APPROACHES TO REVERSING MULTIDRUG-RESISTANCE
Authors: SIKIC BI
Citation: Bi. Sikic, PHARMACOLOGICAL APPROACHES TO REVERSING MULTIDRUG-RESISTANCE, Seminars in hematology, 34(4), 1997, pp. 40-47
MULTIDRUG-RESISTANT HUMAN SARCOMA-CELLS WITH A MUTANT P-GLYCOPROTEIN,ALTERED PHENOTYPE, AND RESISTANCE TO CYCLOSPORINES
Authors: CHEN G DURAN GE STEGER KA LACAYO NJ JAFFREZOU JP DUMONTET C SIKIC BI
Citation: G. Chen et al., MULTIDRUG-RESISTANT HUMAN SARCOMA-CELLS WITH A MUTANT P-GLYCOPROTEIN,ALTERED PHENOTYPE, AND RESISTANCE TO CYCLOSPORINES, The Journal of biological chemistry, 272(9), 1997, pp. 5974-5982
SAQUINAVIR IS A HIGH-AFFINITY SUBSTRATE FOR THE MULTIDRUG TRANSPORTER, P-GLYCOPROTEIN
Authors: WASHINGTON CB DURAN GE SIKIC BI BLASCHKE TF
Citation: Cb. Washington et al., SAQUINAVIR IS A HIGH-AFFINITY SUBSTRATE FOR THE MULTIDRUG TRANSPORTER, P-GLYCOPROTEIN, Clinical pharmacology and therapeutics, 61(2), 1997, p.
SPONTANEOUS OVEREXPRESSION OF THE LONG FORM OF THE BCL-X PROTEIN IN AHIGHLY RESISTANT P388 LEUKEMIA
Authors: KUHL JS KRAJEWSKI S DURAN GE REED JC SIKIC BI
Citation: Js. Kuhl et al., SPONTANEOUS OVEREXPRESSION OF THE LONG FORM OF THE BCL-X PROTEIN IN AHIGHLY RESISTANT P388 LEUKEMIA, British Journal of Cancer, 75(2), 1997, pp. 268-274
TREATMENT OF POOR-PROGNOSIS AML WITH PSC833 PLUS MITOXANTRONE, ETOPOSIDE, CYTARABINE (PSC-MEC)
Authors: ADVANI R SABA HI TALLMAN M ROWE JM WIERNIK PH RAMEK J DUGAN K LUM B VILLENA J SIKIC BI DAVIS E PAIETTA E LITCHMAN M GREENBERG P
Citation: R. Advani et al., TREATMENT OF POOR-PROGNOSIS AML WITH PSC833 PLUS MITOXANTRONE, ETOPOSIDE, CYTARABINE (PSC-MEC), Blood, 90(10), 1997, pp. 2260-2260
PHARMACOLOGICAL CONSIDERATIONS IN THE MODULATION OF MULTIDRUG-RESISTANCE
Authors: FISHER GA LUM BL HAUSDORFF J SIKIC BI
Citation: Ga. Fisher et al., PHARMACOLOGICAL CONSIDERATIONS IN THE MODULATION OF MULTIDRUG-RESISTANCE, European journal of cancer, 32A(6), 1996, pp. 1082-1088
DIFFERENTIAL EXPRESSION OF TUBULIN ISOTYPES DURING THE CELL-CYCLE
Authors: DUMONTET C DURAN GE STEGER KA MURPHY GL SUSSMAN HH SIKIC BI
Citation: C. Dumontet et al., DIFFERENTIAL EXPRESSION OF TUBULIN ISOTYPES DURING THE CELL-CYCLE, Cell motility and the cytoskeleton, 35(1), 1996, pp. 49-58
DOXORUBICIN SELECTION FOR MDR1 P-GLYCOPROTEIN REDUCES SWELLING-ACTIVATED K+ AND CL- CURRENTS IN MES-SA CELLS/
Authors: LUCKIE DB KROUSE ME LAW TC SIKIC BI WINE JJ
Citation: Db. Luckie et al., DOXORUBICIN SELECTION FOR MDR1 P-GLYCOPROTEIN REDUCES SWELLING-ACTIVATED K+ AND CL- CURRENTS IN MES-SA CELLS/, American journal of physiology. Cell physiology, 39(4), 1996, pp. 1029-1036
DIFFERENTIAL SINGLE-STRAND VERSUS DOUBLE-STRAND DNA BREAKAGE PRODUCEDBY DOXORUBICIN AND ITS MORPHOLINYL ANALOGS
Authors: DURAN GE LAU DHM LEWIS AD KUHL JS BAMMLER TK SIKIC BI
Citation: Ge. Duran et al., DIFFERENTIAL SINGLE-STRAND VERSUS DOUBLE-STRAND DNA BREAKAGE PRODUCEDBY DOXORUBICIN AND ITS MORPHOLINYL ANALOGS, Cancer chemotherapy and pharmacology, 38(3), 1996, pp. 210-216
EFFECT OF DIFFERENT MATHEMATICAL-METHODS ON ETOPOSIDE AREA-UNDER-THE-CURVE ESTIMATIONS AND PHARMACODYNAMIC - RESPONSE PREDICTIONS
Authors: MCCAULEY DL LUM BL SIKIC BI
Citation: Dl. Mccauley et al., EFFECT OF DIFFERENT MATHEMATICAL-METHODS ON ETOPOSIDE AREA-UNDER-THE-CURVE ESTIMATIONS AND PHARMACODYNAMIC - RESPONSE PREDICTIONS, Cancer chemotherapy and pharmacology, 37(3), 1996, pp. 286-288
NEURAL-NETWORK (NN) AND LINEAR-REGRESSION LIMITED SAMPLING MODELS (LSM) FOR ETOPOSIDE (E) AUC DETERMINATIONS
Authors: LUM BL SYNOLD TW LANE K CHARNICK SB SIKIC BI
Citation: Bl. Lum et al., NEURAL-NETWORK (NN) AND LINEAR-REGRESSION LIMITED SAMPLING MODELS (LSM) FOR ETOPOSIDE (E) AUC DETERMINATIONS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 2-2
RESISTANCE MECHANISMS IN HUMAN SARCOMA MUTANTS DERIVED BY SINGLE-STEPEXPOSURE TO PACLITAXEL (TAXOL)
Authors: DUMONTET C DURAN GE STEGER KA BEKETICORESKOVIC L SIKIC BI
Citation: C. Dumontet et al., RESISTANCE MECHANISMS IN HUMAN SARCOMA MUTANTS DERIVED BY SINGLE-STEPEXPOSURE TO PACLITAXEL (TAXOL), Cancer research, 56(5), 1996, pp. 1091-1097
METHODS TO DETECT P-GLYCOPROTEIN-ASSOCIATED MULTIDRUG-RESISTANCE IN PATIENTS TUMORS - CONSENSUS RECOMMENDATIONS
Authors: BECK WT GROGAN TM WILLMAN CL CORDONCARDO C PARHAM DM KUTTESCH JF ANDREEFF M BATES SE BERARD CW BOYETT JM BROPHY NA BROXTERMAN HJ CHAN HSL DALTON WS DIETEL M FOJO AT GASCOYNE RD HEAD D HOUGHTON PJ SRIVASTAVA DK LEHNERT M LEITH CP PAIETTA E PAVELIC ZP RIMSZA L RONINSON IB SIKIC BI TWENTYMAN PR WARNKE R WEINSTEIN R
Citation: Wt. Beck et al., METHODS TO DETECT P-GLYCOPROTEIN-ASSOCIATED MULTIDRUG-RESISTANCE IN PATIENTS TUMORS - CONSENSUS RECOMMENDATIONS, Cancer research, 56(13), 1996, pp. 3010-3020
DECREASED MUTATION-RATE FOR CELLULAR-RESISTANCE TO DOXORUBICIN AND SUPPRESSION OF MDR1 GENE ACTIVATION BY THE CYCLOSPORINE PSC-833
Authors: BEKETICORESKOVIC L DURAN GE CHEN G DUMONTET C SIKIC BI
Citation: L. Beketicoreskovic et al., DECREASED MUTATION-RATE FOR CELLULAR-RESISTANCE TO DOXORUBICIN AND SUPPRESSION OF MDR1 GENE ACTIVATION BY THE CYCLOSPORINE PSC-833, Journal of the National Cancer Institute, 87(21), 1995, pp. 1593-1602
NOVEL MECHANISM OF RESISTANCE TO PACLITAXEL (TAXOL(R)) IN HUMAN K562 LEUKEMIA-CELLS BY COMBINED SELECTION WITH PSC-833
Authors: JAFFREZOU JP DUMONTET C DERRY WB DURAN G CHEN G TSUCHIYA E WILSON L JORDAN MA SIKIC BI
Citation: Jp. Jaffrezou et al., NOVEL MECHANISM OF RESISTANCE TO PACLITAXEL (TAXOL(R)) IN HUMAN K562 LEUKEMIA-CELLS BY COMBINED SELECTION WITH PSC-833, Oncology research, 7(10-11), 1995, pp. 517-527
CYCLOSPORINE-A INCREASES SERUM CORTISOL-LEVELS IN RABBITS
Authors: CUFER T VRHOVEC I SKRK J PFEIFER M PAJK B ZAKOTNIK B FILIPIC B RODE B SIKIC BI
Citation: T. Cufer et al., CYCLOSPORINE-A INCREASES SERUM CORTISOL-LEVELS IN RABBITS, Anti-cancer drugs, 6(4), 1995, pp. 615-618
Risultati: 1-25 | 26-45